Acquisition
Nov 2025Colossal announced its first acquisition, ViaGen Pets & Equine, an Austin-based animal-cloning, cryopreservation, and biobanking company. Financial terms were not disclosed.
SourceCompany research
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Overview
Colossal Biosciences is a privately held biotechnology and genetic-engineering company developing technologies for functional de-extinction, endangered-species conservation, genomic research, and ecosystem restoration. Its work combines CRISPR gene editing, ancient-DNA analysis, synthetic biology, cloning, assisted reproduction, computational biology, and artificial-womb research.
Primary product
A de-extinction and species-restoration technology platform, currently focused on woolly mammoth, dire wolf, dodo, thylacine, giant moa, and bluebuck programs.
Founded
2021
Headquarters
Dallas, Texas, United States
Team size
201-500
Industry
Biotechnology Research
Sub-industry
Genetic engineering, conservation biotechnology, synthetic biology, and de-extinction
Offices
Dallas, Texas, United States (headquarters)
Austin, Texas, United States (1401 Lavaca Street, Unit 155)
Business model
Venture-backed R&D platform
Government and conservation partnerships
Technology licensing and spinouts
Potential biodiversity-credit and ecotourism revenue
Animal cloning and genetic-preservation services through ViaGen
Funding
Stage
Series C / late venture-backed private company
Total raised
$625M
Latest round
Series C plus reported extension · Jan 2025
Latest amount
$320M
Jan 2025 · TWG Global
$120M
Jan 2023
Mar 2022
Sep 2021
People & investors
Leadership
Co-founder and Chief Executive Officer
George Church
Co-founder and Scientific Adviser
Co-founder, Chief Global Strategy and Legal Officer, and Board Member
Chief Operating Officer
Chief Science Officer
Chief Biology Officer
Chief Animal Officer and Executive Director, The Colossal Foundation
General Counsel
Co-founder, former Chief Operating Officer; current adviser
Work & culture
The company presents itself as a mission-driven, interdisciplinary science and engineering organization focused on ambitious conservation and genomic goals. Public hiring and employer-review signals indicate a growing team, strong reported compensation, and generally positive work-life and culture ratings, but detailed official benefits and policies are not publicly established.
Compensation
Public third-party employer data reports a 4.2/5 overall rating and 4.5/5 compensation rating, but Colossal does not appear to publish a comprehensive company-wide compensation framework. Role-specific salary information is limited.
Product & market
Pricing
Not publicly disclosed. Colossal has described a mixed model involving government and conservation partnerships, future technology commercialization, spinouts, biodiversity credits, ecotourism, media, and animal-cloning services through ViaGen.
Differentiators
- —One of the first companies to apply CRISPR and modern reproductive technologies to functional de-extinction.
- —Combines ancient-DNA research, gene editing, synthetic biology, cloning, computational biology, and reproductive technology in one platform.
- —Uses extinct-species programs to develop conservation tools for living endangered species.
- —Has produced genetically engineered animals carrying selected traits associated with extinct species, including the announced dire-wolf program.
- —Operates a large integrated Dallas research facility and has built a portfolio of spinout companies around platform technologies.
Technology
CRISPR gene editing
Ancient-DNA sequencing and comparative genomics
Synthetic biology
Computational biology and AI
Stem-cell and cell-line engineering
Cloning
Cryopreservation and biobanking
Assisted reproduction and IVF
Artificial-womb research
Primordial germ-cell culture and avian genetic engineering
Python
Ruby
Java
C
Bash
Perl
Linux
Git
Docker
Kubernetes
Customers
U.S. government conservation agencies
United Arab Emirates government and conservation stakeholders
Save the Elephants
Re:wild
Other conservation organizations and academic partners
Competitors
Revive & Restore
ViaGen and other animal-cloning providers
Mammoth Biosciences
eGenesis
Pairwise
Genetic-engineering and conservation-biotechnology startups
Scale & contact
Estimated revenue
$0-$10 million annually; public reporting indicates the company was pre-revenue at its January 2025 round and had begun generating some revenue by 2026, but no audited figure is publicly available.
Estimated monthly visits
228K
Traffic estimate as of May 2026
Signals & risks
Other
Apr 2025The company’s dire-wolf announcement generated substantial scientific debate over whether genetically edited gray wolves with selected extinct-species traits should be described as true de-extinction.
SourceOther
Jan 2025Colossal’s reported $10.2 billion valuation and large Series C occurred while its flagship de-extinction programs remained pre-commercial and technically uncertain, creating execution, valuation, and commercialization risk.
SourceLatest news
TechCrunch · Jul 2026
TechCrunch reported that Colossal was seeking additional financing at a possible $20 billion-$30 billion valuation and had begun generating revenue, while noting that the size and lead investor of the potential round were not public.
WIRED · Jun 2026
The U.S. government partnered with Colossal to develop a national repository of genetic material from endangered and threatened species.
Colossal Biosciences · Nov 2025
Colossal announced its first acquisition, adding ViaGen’s cloning, cryopreservation, assisted-reproduction, and biobanking capabilities to its species-preservation platform.
TechCrunch · Apr 2025
Coverage of Colossal’s genetically engineered dire-wolf pups and the scientific debate over whether the animals constitute de-extinction or a proxy species.
TechCrunch · Jan 2025
Colossal announced a $200 million Series C led by TWG Global at a reported $10.2 billion valuation. The article describes potential revenue streams including technology spinouts, government collaborations, and biodiversity credits.
Jobs and careers at Colossal Biosciences
12 jobs at Colossal Biosciences
Scientist, Cell Engineering
On-site
Research & Development
Dallas, TX; Dallas, Texas, United States
1d ago
On-site
Full-time
Research Associate/Senior Research Associate, Cell Engineering
On-site
Research & Development
Dallas, TX; Dallas, Texas, United States
1d ago
On-site
Full-time
Summer 2027 Internships - General Interest Posting
On-site
Corporate
Dallas, TX; Dallas, Texas, United States
2w ago
On-site
Full-time
General Assistant/Coordinator
On-site
Corporate
Dallas, TX; Dallas, Texas, United States
3w ago
On-site
Full-time
Entertainment Producer
On-site
Corporate
Dallas, TX; Dallas, Texas, United States
3w ago
On-site
Full-time
Junior Editor
On-site
Corporate
Dallas, TX; Dallas, Texas, United States
3w ago
On-site
Full-time
Cinematographer
On-site
Corporate
Dallas, TX; Dallas, Texas, United States
3w ago
On-site
Full-time
Research Associate, Stem Cell Engineering
On-site
Research & Development
Dallas, TX; Dallas, Texas, United States
1mo ago
On-site
Full-time
Director, Artificial Womb Technology Research
On-site
Exogenous Development
Dallas, TX; Dallas, Texas, United States
1mo ago
On-site
Full-time
Clinical Veterinarian
On-site
Animal Operations
Dallas, TX; Dallas, Texas, United States
3mo ago
On-site
Full-time
Laboratory Automation Engineer
On-site
Laboratory Operations
Dallas, TX; Dallas, Texas, United States
3mo ago
On-site
Full-time
General Interest - Join our Colossal Community
On-site
Corporate
Dallas, TX; Anywhere in the United States; Dallas, Texas, United States
6mo ago
On-site
Full-time